2.50
Hdl Handle:
http://hdl.handle.net/10541/95981
Title:
Optimal control of cyclophosphamide-induced emesis.
Authors:
Stewart, Alan L
Abstract:
Cyclophosphamide induces moderate to severe emesis. The severity of emesis is dependent on the dose of cyclophosphamide and on the addition of other cytotoxic drugs. A review of the literature dividing studies according to the dose of cyclophosphamide and the specific cytotoxic combination shows that ondansetron plus dexamethasone provides optimal antiemetic therapy in patients receiving standard or high-dose cyclophosphamide (> or = 450 mg/m2). These studies also show that it is important to give antiemetic therapy to cover the prolonged duration emesis and nausea induced by these regimens, e.g. intravenous CMF/(F)AC/(F)EC. For continuous 'oral' (low-dose) CMF chemotherapy, oral ondansetron or oral metoclopramide plus intravenous (or possibly oral) dexamethasone are effective antiemetic therapies.
Affiliation:
Department of Clinical Oncology, Christie Hospital, Manchester, UK.
Citation:
Optimal control of cyclophosphamide-induced emesis. 1996, 53 Suppl 1:32-8 Oncology
Journal:
Oncology
Issue Date:
Jun-1996
URI:
http://hdl.handle.net/10541/95981
PubMed ID:
8692548
Type:
Article
Language:
en
ISSN:
0030-2414
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorStewart, Alan Len
dc.date.accessioned2010-04-08T10:38:27Z-
dc.date.available2010-04-08T10:38:27Z-
dc.date.issued1996-06-
dc.identifier.citationOptimal control of cyclophosphamide-induced emesis. 1996, 53 Suppl 1:32-8 Oncologyen
dc.identifier.issn0030-2414-
dc.identifier.pmid8692548-
dc.identifier.urihttp://hdl.handle.net/10541/95981-
dc.description.abstractCyclophosphamide induces moderate to severe emesis. The severity of emesis is dependent on the dose of cyclophosphamide and on the addition of other cytotoxic drugs. A review of the literature dividing studies according to the dose of cyclophosphamide and the specific cytotoxic combination shows that ondansetron plus dexamethasone provides optimal antiemetic therapy in patients receiving standard or high-dose cyclophosphamide (> or = 450 mg/m2). These studies also show that it is important to give antiemetic therapy to cover the prolonged duration emesis and nausea induced by these regimens, e.g. intravenous CMF/(F)AC/(F)EC. For continuous 'oral' (low-dose) CMF chemotherapy, oral ondansetron or oral metoclopramide plus intravenous (or possibly oral) dexamethasone are effective antiemetic therapies.en
dc.language.isoenen
dc.subject.meshAntiemetics-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCyclophosphamide-
dc.subject.meshDoxorubicin-
dc.subject.meshEpirubicin-
dc.subject.meshFluorouracil-
dc.subject.meshHumans-
dc.subject.meshLomustine-
dc.subject.meshMethotrexate-
dc.subject.meshProcarbazine-
dc.subject.meshRandomized Controlled Trials as Topic-
dc.subject.meshVomiting-
dc.titleOptimal control of cyclophosphamide-induced emesis.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Oncology, Christie Hospital, Manchester, UK.en
dc.identifier.journalOncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.